PBYI Q4 2022 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M+18.6% YoY

Gross Profit

$49M74.4% margin

Operating Income

$10M15.3% margin

Net Income

-$6M-8.5% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+15.0%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$683,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$222M

Total Liabilities

$200M

Stockholders' Equity

$22M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$55M	+18.6%
Gross Profit	$49M	$43M	+12.4%
Operating Income	$10M	-$24M	+142.5%
Net Income	-$6M	$4M	-232.7%

Revenue Segments

Product

$54M82%

Royalty

$12M18%